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ABSTRACT  Heparan  sulfate and heparin, two sulfated glycosaminoglycans (GAGs), extracted 
collagen-tailed acetylcholinesterase (ACHE) from the extracellular matrix (ECM) of the electric 
organ of  Discopyge  tschudii.  The  effect  of  heparan sulfate and  heparin  was  abolished  by 
protamine;  other GAGs could not extract the esterase. The solubilization  of the asymmetric 
AChE apparently  occurs through  the  formation  of a soluble AChE-GAG  complex  of 30S. 
Heparitinase treatment but not chondroitinase ABC treatment of the ECM released asymmetric 
AChE forms. This provides direct  evidence for the  in vivo  interaction  between  asymmetric 
AChE and  heparan sulfate residues of the  ECM. Biochemical analysis of the  electric  organ 
ECM showed that sulfated GAGs bound to proteoglycans account for 5% of the total  basal 
lamina. Approximately  20% of the total GAGs were susceptible to heparitinase or nitrous acid 
oxidation which degrades specifically heparan sulfates, and ~80% were susceptible to diges- 
tion with  chondroitinase  ABC, which  degrades chondroitin-4 and -6 sulfates and dermatan 
sulfate. Our experiments provide evidence that asymmetric AChE and carbohydrate compo- 
nents of proteoglycans are associated in the ECM; they also indicate that a heparan sulfate 
proteoglycan  is involved  in the anchorage of the collagen-tailed AChE to the synaptic basal 
lamina. 
Acetylcholinesterase (ACHE) ~ is one of the major functional 
components of the  neuromuscular junction  of both muscle 
and the electric organ, and is responsible at least in part for 
terminating the actions of the neurotransmitter acetylcholine 
released  from  the  presynaptic  nerve  terminals  (1).  AChE 
occurs in  several molecular forms that can be separated by 
velocity sedimentation. These molecules have been shown to 
belong to two distinct structural classes:  the asymmetric and 
the globular forms (2). The asymmetric forms are composed 
of tetramers  of the  globular  subunits  attached  to  a  long, 
collagen-like tail (3, 4). 
We are interested in the study of the interactions involved 
~Abbreviations used in this paper: ACHE, acetylcholinesterase;  ECM, 
extracellular matrix; GAGs, glycosaminoglycans. 
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in the attachment of asymmetric AChE to the synaptic extra- 
cellular matrix (ECM).  AChE  occupies <0.1%  of the  total 
area of the basal lamina at the nerve-muscle synapse, which 
suggests  a  high degree of specificity in its distribution.  The 
factors involved in the AChE-ECM interaction are unknown. 
We have previously reported on the association of collagen- 
tailed AChE with ECM of cultured  mouse muscle cells  (5) 
and of the electric organ of Electrophorus and Torpedinidae 
fishes (6).  The three most prevalent classes of molecules in 
the ECM are collagen type IV; glycoproteins, including lam- 
inin,  entactin,  nidogen,  and  fibronectin;  and  proteoglycans 
formed by complex sugars called glycosaminoglycans (GAGs) 
(7-11). Multiple interactions of ECM components could play 
a  role in the deposition of asymmetric ACHE.  Accordingly, 
985 the relationship of collagen-tailed AChE with various ECM 
components has been studied (12,  13), and conflicting evi- 
dence has been obtained for fibronectin, laminin, and collagen 
type V (14,  15). Moreover, because all the above studies have 
been done in a test tube with isolated macromolecules, the 
real significance of such results is unknown. 
We have previously communicated that heparin, a sulfated 
GAG, specifically  solubilizes  the collagen-tailed AChE from 
homogenates of rat  diaphragm  muscle  enriched in  motor 
endplates (16). These results provide the first evidence for the 
in situ involvement of GAGs in the anchorage of the asym- 
metric ACHE. Supporting evidence for the above contention 
comes from the fact that purified Electrophorus  AChE binds 
to a heparan sulfate proteoglycan extracted from the murine 
Engelbreth-Holm-Swarm sarcoma  (14).  Here  we  have  ex- 
tended our studies to the ECM of the electric organ of the 
electric ray by (a) showing the specificity of the solubilizing 
effect of heparan sulfate and heparin on the collagen-tailed 
ACHE, including the formation of a soluble complex between 
GAGs and the 16S ACHE, (b) describing the solubilization of 
asymmetric AChE by heparitinase, and (c) characterizing the 
distribution of GAGs, including the identification of heparan 
sulfate as one of the carbohydrate components of proteogly- 
cans of the electric organ ECM. 
MATERIALS AND  METHODS 
The following chemicals were used: BW284c51 dibromide, the AChE inhibitor, 
was obtained from Burroughs Wellcome Co. (Triangle Park, NC). Hyaluronic 
acid  from human umbilical  cord, chondroitin  sulfate from shark  and whale 
cartilage, heparin  from bovine lung, and porcine intestinal mucosa and chon- 
droitinase  ABC were obtained  from Sigma Chemical  Co.  (St. Louis,  MO). 
Heparan sulfate and heparitinase were purchased from Miles Laboratories Inc. 
(Elkhart,  IN). Heparin-agarose  resin was purchased  from Bethesda Research 
Laboratories (Gaithersburg, MD). [35S]Na2SO4 (100 Ci/mmol) was purchased 
from New England Nuclear (Boston, MA). Other reagents, where not specified, 
were obtained  from commercial  sources. Discopyge tschudii, a Torpedinidae 
electric fish (6,  17), was caught  in  the Pacific Ocean  near  the port of San 
Antonio, Central Chile. 
Preparation of ECM-like Material 
Frozen  electric organ  (-80"C) was homogenized  1/3 (wt/vol)  in 50  mM 
Tris-HCl, pH 8.4, containing  protease inhibitors,  1 mM benzamidine  hydro- 
chloride,  20  U/ml  aprotinin,  100  mM  6-aminohexanoic  acid, and  5  mM 
EDTA. The homogenate was centrifuged at 15,000 g for 20 min. The precipitate 
was rehomogenized  in  50  mM Tris  HCI, pH 8.4, 0.5% Triton  X-100,  and 
proteinase inhibitors with constant  stirring at 4"C for 10 min. This procedure 
was repeated four times, and the final insoluble precipitate ECM-like material 
was used for the experiments described in this paper. 
Sedimentation Analysis of AChE 
The  molecular  forms of AChE  were  separated  on  sucrose  gradients  as 
described  previously  (18, 19). In general,  an  extract  obtained  from frozen 
electric organ was prepared and clarified by centrifugation  at  15,000 g for 15 
min. Aliquots (100-200  tal) of the resulting supernatants  were loaded on a 5- 
20% linear sucrose gradient made up in 50 mM Tris-HC1 (pH 8.4) buffer with 
0.5%  Triton  X-100. Sedimentation  ultracentrifugation  was performed  in  a 
Beckman L5-65 ultracentrifuge (Beckman Instruments, Inc., Palo Alto, CA) in 
a SW65 rotor at 215,000 g for 8 or 3 h at 4"C. Sedimentation  coefficients for 
AChE  forms were determined  by comparison  with  that  for B-galactosidase 
(16.1S). This enzyme was measured by the method of Craven et al. (20). 
Affinity Chromatography of AChE in 
Heparin-Agarose 
The heparin-agarose  was poured as 0.2-ml columns in l-ml pipette tips (0.4 
x  2.0 cm) and washed with at least  l0 vol of buffer containing  50 mM Tris- 
HCI (pH 7.4) and 0.2 M NaCI. Chromatography was done at room temperature. 
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After the enzyme (in 0.2 M NaCI) was applied to the column and washed with 
at least l0 vol of Tris-NaCl  buffer, adsorbed material was eluted with 2 ml of 
2 mg/ml heparin in 50 mM Tris-HC1 at pH 7.4 containing 0.2 M NaC1. 
AChE Assay 
AChE  activity  was  measured  by  the  method  of Ellman  et  al.  (21). All 
determinations  were done at 37°C in a  l ml reaction  mixture containing  100 
mM sodium phosphate buffer (pH 7.0), 0.75 mM acetylthiocholine iodide, and 
0.3 mM dithiobis-nitrobenzoic  acid. BW284c51 dibromide (10 #M) was used 
as the AChE-specific inhibitor. 
Release of AChE-ECM by GAG- 
degradating Enzymes 
ECM (10 mg wet wt) resuspended in  10 mM Tris-HC1, pH 7.4, 100 mM 
NaCl, 5 mM calcium acetate, 5 mM benzamidine, 20 U/ml aprotinin,  0.05 M 
6-aminohexanoic  acid, and  l  mg/ml bovine  serum albumin  was incubated 
with different amounts of Flavobacterium heparinum heparitin  lyase (hepari- 
tinase) or chondroitinase ABC during 50 rain at 37°C in a final volume of 100 
#l.  At the end of the incubation,  the mixture was diluted with 0.4 ml of the 
same medium without ECM and enzymes. The AChE activity released by the 
enzymatic  treatments  was separated  from the  ECM by loading the  mixture 
over a cushion of 0.5 ml of 45% sucrose. Then after centrifugation at maximal 
speed in a Eppendorf centrifuge for l0 min, 0.5 ml were taken from the top of 
the centrifuge tube, and the AChE activity was determined as described above. 
Control experiments showed that asymmetric AChE did not sediment at low 
ionic strength conditions through the sucrose cushion. Aliquots of the incuba- 
tion medium in the presence or absence of heparitinase (1.5 U) were loaded on 
5-20% sucrose density gradients and run as described previously. 
Isolation of Sulfated GAGs by Alkaline Treatment 
ECM-like material (50 mg dry wt) was homogenized in 0.1 M Tris-HCl pH 
8.5 in the presence of 3% Triton  X-100 with constant stirring at 4°C, and the 
homogenate was then centrifuged at 10,000 g for 15 rain. The resulting pellet 
was resuspended in 0.01 M NaOH and  l  M NaBH4 (22) and hydrolyzed at 
45"C for 24  h. After the pH was neutralized  with  5 M acetic acid  and the 
solution was centrifuged at 10,000 g for 15 rain, the free GAGs were precipitated 
from the supernatant  with cold 70% ethanol.  Samples were resuspended and 
treated  with heparitinase,  chondroitinase  ABC, or nitrous  acid  as described 
below. 
GAGs Digestion 
GAGs digestion was as follows: (a) Treatment with chondroitinase ABC was 
performed in a buffer consisting of 50 mM Tris-HCl and 100 mM NaCl (pH 
7.0). Digestion with 0.05 U/ml was carried out for 3-5  h at 37'C  (23). (b) 
Heparan sulfate was cleaved by two  methods:  (i) digestion  with  0.1  U/ml 
Flavobacterium heparinum heparitin sulfate lyase (heparitinase) in 50 mM Tris- 
HCI and 5 mM calcium acetate (pH 7.0) for 3-5 h at 39"C, and repeated for l 
h with fresh enzyme (24), or (ii) cleavage by nitrous acid (prepared by mixing 
equal volumes of I M sodium nitrite and l N HCl) for 3 h at room temperature 
(25, 26). Both the enzyme-digested samples and the nitrous acid-treated  sam- 
ples were lyophilized to dryness. GAGs and the products of the above reactions 
were  separated  by  cellulose  acetate  electrophoresis  or  chromatography  on 
Sepharose CL-6B. 
Cellulose Acetate Electrophoresis of GAGs 
Electrophoresis  of individual  GAG  standards,  ECM-GAGs  or  digested 
samples, was carried out at 4"C in 0.2 M calcium acetate (pH 7.0) at 5.0 mA 
for 2 h on cellulose acetate membranes in a Beckman Microzone Instrument. 
The position of the GAGs was then visualized by staining the electrophoreto- 
grams by immersion in an alcian blue solution (0.1% alcian blue in 0.1% acetic 
acid) for 5 min and destained with  10% acetic acid (27). The identity of the 
extracted GAGs was determined  by comparing the position of the alcian blue 
staining to that of the known GAGs standards. For quantitative determination 
of  the GAG, the strips were cleared, dried, and scanned on a Canalco densitom- 
eter. 
Column Chromatography 
Sepharose CL-6B gel filtration  columns (100 x  1.4 cm) were prepared  in 
and eluted with 0.2 M sodium acetate and 0.2 M sodium sulfate, pH 7.0 (28). Their flow rates were ~0.1 ml/min. The void  (Iio)  and total (V0 volumes  of  the 
columns were determined by eluting dextran blue-2,000 (for Iio) and [35S]- 
Na2SO4 (for Vt). The content of uronic acid was determined by the modified 
carbazole reaction, with glucuronic  acid as the standard (29). 
RESULTS 
Heparan  Sulfate and Heparin  Release 
Asymmetric AChE from  the ECM as a 
30S Complex 
When the  ECM-like  fraction of Discopyge electric  organ 
was resuspended in Tris-Triton buffer with and without hep- 
aran sulfate  or heparin and the supernatants  obtained after 
centrifugation were assayed for ACHE, it was found that most 
of the residual  enzyme activity was released  in the sulfated 
GAGs-containing  medium  (Fig.  l).  Hyaluronic  acid  and 
chondroitin sulfate did not solubilize any additional activity 
from the ECM. On the other hand, protamine, a polycationic 
agent  that  has  been  shown  specifically  to  eliminate  other 
effects of heparin (30), neutralized the solubilizing activity of 
both  heparan  sulfate  and  heparin  (Table  I).  Both  results 
suggest that a specific domain of heparan sulfate and heparin 
is responsible for the detachment of AChE from its anchoring 
site in the basal lamina. When the AChE activity released by 
the GAGs from the ECM was analyzed by sucrose gradient 
sedimentation,  a  major peak  of asymmetric  16S  form was 
observed (data not shown). Previous studies with rat muscle 
homogenates (16) and crude membrane fractions of Disco- 
pyge  electric  organ  (17)  have  also  indicated  a  preferential 
solubilization of asymmetric AChE forms, but knowing that 
a  great proportion  (20-50%)  of the  tailed  AChE species is 
localized in intracellular compartments (31-34),  it has been 
conceptually important to establish that the AChE bound to 
the ECM is also detached by sulfated GAGs. 
All the above studies have been done with sucrose gradient 
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FIGURE 1  Solubilization  of AChE activity from the electric  organ 
of Discopyge tschudii by heparan sulfate  and  heparin.  The  ECM- 
like material  was  resuspended  in  50  mM Tris-HCI, pH  8.4,  plus 
0.5% Triton X-100 and separated in aliquots.  Heparin and heparan 
sulfate dissolved in Tris-Triton were added to the different samples 
to obtain the final concentration shown in the figure (O, heparin; 
O,  heparan  sulfate).  After homogenization, the different  aliquots 
were centrifuged at 15,000 g during 20 min, and the AChE activity 
was  determined  in  the  supernatant.  Each point  represents  the 
average of two different experiments run in triplicate. AChE activity 
is expressed as units per gram  ECM, and  1 U corresponds to 1.0 
#tool of substrate  hydrolyzed in 1 min at 37"C. 
TABLE  I.  Solubilization  of AChE Activity from ECM-like Material of 
Electric Organ 
AChE activity 
Substance applied  solubilized  Extraction 
i~moles/min per g  qb 
Buffer alone  0.99 4- 0.13  0 
+  Hyaluronic acid  1.03 4- 0.05  4 
+  Chondroitin sulfate  1.09 4- 0.17  10 
+  Heparin +  protamine  1.03 4- 0.14  4 
+  Heparan sulfate +  protamine  0.96 4- 0.09  0 
+  Heparan sulfate  5.48 4- 0.12"  453 
+  Heparin  7.30 4- 0.13"  637 
The ECM-like material was homogenized in 50 mM Tris-HCl (pH 8.4) and 
0.5%  Triton  X-100  or  in  the  same extraction solution  plus:  2.0  mg/ml 
hyaluronic acid; 5 mg/ml chondroitin sulfate; 0.5 mg/ml of heparin plus 2.0 
mg/ml  of  protamine; 0.5  mg/ml  of  heparan  sulfate  plus  2.0  mg/ml  of 
protamine; 0.5 mg/ml of heparin  sulfate; and 0.5 mg/ml of heparin.  The 
homogenates were centrifuged  at 20,000 g for 20 min. Aliquots of each of 
the supernatants were added to the assay containing 0.75 mM acetylthio- 
choline iodide and  0.1  mM  iso-octamethyl  pyrophosphoramide. Assays 
were conducted at 37*C for 10-20 rain. Activity values correspond to the 
mean _+ S.E.M. of five experiments. Percent extraction was calculated taking 
buffer-extracted  activity as the 0% (second column). 
* P <  0.001, as compared to control without heparin and without heparan 
sulfate. 
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FIGURE  2  Sedimentation  profile  of  GAG-induced  AChE  aggre- 
gates. 200 #1 of a  supernatant containing  heparin  prepared from 
ECM-like  material was  loaded  in  5-20%  sucrose  gradient  in  the 
presence of heparin (2.0 mg/ml) with (O) or without (@) 1.0 M  NaCI. 
Sedimentation was performed for 3 h at 46,000 rpm in a Beckman 
SW.65  rotor. Gradients were fractionated  in 34  fractions and ali- 
quots assayed for AChE activity by the method of Ellman et al. (21). 
The black arrow indicates the sedimentation position of/~-galacto- 
sidase (16.1) assayed by the method of Craven et al. (20). The short 
open  arrow  indicates  the  sedimentation  80S  of  the  low  ionic 
strength  aggregates obtained after dialysis of asymmetric enzyme 
extracted with 1.0 M  NaCl. 
prepared  in  1  M  NaC1.  However,  if the  GAG-solubilized 
esterase  is sedimented  under low ionic strength  conditions, 
the majority of the AChE activity sediments at the bottom of 
the gradient,  suggesting the presence of an aggregate of the 
16S ACHE. To be certain that this was in fact the case, the 
GAG-extracted AChE activity was separated by sedimenta- 
tion analysis with and without  1 M  NaC1, but only for 3 h. 
Fig. 2 shows one of such experiments. In the low salt medium, 
it was observed that most of the esterase activity gave rise to 
polydisperse-aggregated components sedimenting around 30S 
(Fig. 2, closed circles), whereas at high ionic strength condi- 
tions,  the  16S remained  unaggregated (Fig. 2,  open  circles). 
BRANDAN ET AL.  AChE-Heparan  Interaction in the Extracellular  Matrix  987 Note  that  the  globular  6.55  form  (fraction  30)  remained 
unaggregated in both conditions.  The data suggest  that sul- 
fated GAGs removed AChE from the ECM by a mechanism 
that involves the formation of soluble complex between the 
GAG and the asymmetric 165 esterase. 
Binding of ECM-AChE to Sulfated GAG 
To prove the  direct interaction  of Discopyge 165  AChE 
with the sulfated GAG, affinity chromatography in heparin- 
agarose was done. When a preparation of AChE containing a 
small amount of asymmetric forms and a higher proportion 
of  globular forms (Fig. 3 a) was dialyzed against low salt buffer, 
passed through  a  heparin-agarose column,  and  the  eluate 
analyzed by sucrose gradient sedimentation, all the recovered 
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FIGURE  3  Evaluation of the specificity of the heparin-agarose col- 
umn  by  sucrose  gradient sedimentation of  the AChE  molecular 
forms. 1 g of Discopyge electric organ was homogenized in 50 mM 
Tris-HCI,  pH  7.4,  1.0 M  NaCI and centrifuged at 15,000 g per 20 
,in. The supernatant was dialyzed against Tris buffer during 4 h, 
resuspended in the same buffer plus 0.2 M NaCI, and then loaded 
on the heparin-agarose column equilibrated in 0.2 M  NaCI, 5 mM 
EDTA, 20 U/ml aprotinin, 1 mM benzamidine, 0.1 mg/ml bacitracin, 
buffered with 50 mM Tris-HCI  at pH 7.4. Both the passing through 
and the AChE activity eluted by heparin were recovered. Aliquots 
of the sample loaded in the column (a), the passing through (b), 
and the esterase  activity specifically eluted  by  heparin (c)  were 
sedimented in linear sucrose gradients containing 50 mM Tris-HCI, 
pH  7.4,  0.5% Triton and  1.0 M  NaCI,  for 8  h at 46,000  rpm, as 
described in Fig. 2. The arrows indicate the sedimentation position 
of/~-galactosidase  (16.1S). 
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AChE activity corresponded to globular forms of 6.55 (Fig. 
3b).  However,  the  activity  specifically eluted  by  heparin 
mainly corresponded to the asymmetric 165 AChE form (Fig. 
3 c).  The  results  support  the  idea  that  heparin  binds  to  a 
specific site of the asymmetric AChE from the electric organ. 
Similar results have been  observed with  rat  muscle AChE 
(35). 
Heparitinase Solubilizes Asymmetric AChE from 
the ECM 
An independent and more direct criterion, to establish the 
in situ interaction of AChE and the carbohydrate components 
of proteoglycans in  the  electric  organ  ECM,  is the  use  of 
enzymes that  degrade  specific GAGs.  In  this  context,  we 
incubated ECM fractions with and without heparitinase (de- 
grades specifically heparan  sulfate) or chondroitinase  ABC 
(degrades chondroitin-4 and -6 sulfates and dermatan sulfate) 
for 50 ,in  at 37"C. After separation of the particulate ECM 
through a  cushion  of 45%  sucrose,  the  AChE  activity was 
determined.  As  Fig.  4A  indicates,  increasing  amounts  of 
heparitinase, but not chondroitinase ABC, were able to release 
esterase to the incubation medium. The ECM of Discopyge 
electric  organ  mainly consists  of asymmetric AChE  forms 
(AI2 and A8) (17), therefore it is very likely that heparitinase 
releases these AChE species from the ECM. Fig.  4B clearly 
shows that in fact the heparan sulfate hydrolase liberated only 
collagen-tailed AChE forms. The above results provide direct 
evidence for the in vivo interaction between the asymmetric 
AChE and heparan sulfate proteoglycans present in the elec- 
tric organ ECM. 
Heparan Sulfate and Chondroitin Sulfate 
Proteoglycans Are Present in the ECM of the 
Electric Organ 
To evaluate both the  amount  and the  different types of 
proteoglycans present in the electric organ ECM, the ECM 
was treated with  alkaline borohydride to  release the  single 
sulfated GAG chain present in the ECM-proteoglycans. The 
total  amount  of GAGs was  determined  by measuring the 
uronic acids:  -50 ~g of uronic acid was found per milligram 
(dry weight) of ECM-like material; consequently, -5% of the 
electric organ ECM is considered to represent the carbohy- 
drate component of proteoglycans. 
Cellulose acetate electrophoresis of the isolated GAG frac- 
tion revealed the presence of two major spots (Fig. 5A). The 
migration of one of them corresponded to that of the heparan 
sulfate  standard,  and  we  will  call  this  spot  the  HS  peak, 
whereas the other spot corresponded to chondroitin-6-sulfate 
(CS peak). When alkaline hydrolyzates of whole ECM were 
treated with chondroitinase ABC before electrophoresis in the 
calcium acetate buffer system, the CS  peak was no  longer 
present, the other spot (HS peak) decreased -50%, and the 
new HS peak was more symmetrical than was the original 
one (Fig. 5 C). If  samples were treated with nitrous acid, ~50% 
of the HS peak was removed (Fig. 5 B) and the remaining HS 
peak  seemed  to  migrate  ahead  of the  original  peak  and 
appeared to correspond to the shoulder presented by the HS 
peak of  the ECM sample. Finally, when the ECM-GAGs were 
first treated with chondroitinase ABC and then with nitrous 
acid, almost all the GAGs were digested (Fig. 5 D). To establish 
the absolute amount of nitrous acid-sensitive material present 160 
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FIGURE 4  Release  of asymmetric  AChE forms  bound to  ECM of 
the electric organ by heparitinase. (A) The ECM was incubated with 
various amounts of purified heparitinase (&) or chondroitinase  ABC 
(A) for 50 min at 37°C. AChE activity released to the incubation 
medium was assayed as described in the Materials and  Methods 
section.  The values  presented  correspond to the  difference be- 
tween each treatment and the AChE released in the absence of the 
enzyme. (B) Sedimentation profile of the AChE activity released in 
10 mM Tris-HCI pH 7.4, 100 mM NaCI buffer, with (0) and without 
(O) 1.5 U of purified heparitinase. Only the asymmetric  forms A12 
and A8 were released by heparitinase.  Note that due to the long 
incubation (50 min) at 37°C, the control sample also presents small 
amounts of both asymmetric  AChE forms. The arrow indicates the 
sedimentation of/~-galactosidase (16.1S). 
in the ECM-GAGs, the intensity of  the spots with and without 
nitrous acid treatment were measured in a densitometer for 
several different samples. Table II shows that 21% of the total 
GAGs disappeared after nitrous acid oxidation, indicating the 
presence of heparan sulfate within the ECM-GAGs. 
Another way to characterize sulfated GAGs is by using gel 
filtration columns (26, 28). For these experiments, aliquots of 
the hydrolyzate samples were chromatographed on Sepharose 
CL-6B columns. Fig. 6A shows that two main classes of GAG 
chains with Kay of 0.3  and 0.53  were present in the electric 
organ ECM. Heparitinase treatment of the samples released 
~ 18% of the total uronic acid as low molecular weight ma- 
terial that eluted close to the column total volume; this occurs 
with a concomitant decrease in the peak of K~, =  0.53 (Fig. 
6 B). This result also indicates the presence of heparan sulfate 
in the ECM of Discopyge electric organ, by a criterion inde- 
pendent of the nitrous acid oxidation. Chondroitinase ABC 
treatment  of the  sample  degraded  uronic  acid-containing 
material (75 %), and the fragments eluted at a K~v of 0.96 close 
to the column total volume; this occurred with the concomi- 
tant disappearance in the other main peak of ECM-GAGs 
located at a Kay of 0.3 (Fig. 6 C). In either case, there was no 
detectable change in the elution profile of the resistant peaks. 
To summarize, we have reliably identified the presence of 
heparan sulfate in the ECM of the electric organ because (a) 
a specific spot of ECM-GAGs has the same electrophoretic 
mobility than does the heparan sulfate standard in the calcium 
acetate system, (b) 20%  of the ECM-GAGs disappear after 
nitrous acid oxidation, (c) heparitinase treatment of  the ECM- 
GAGs destroys 18 % of the total GAGs shown by chromatog- 
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FIGURE .5  Gel scans of GAGs components isolated from the ECM 
of Discopyge electric organ after cellulose acetate electrophoresis. 
GAGs  obtained from  ECM-like  material  by alkaline-borohydride 
treatment were submitted  to  electrophoresis  in  0.2  M  calcium 
acetate {pH 7.0) at 5 mA per strip for 2 h at 4°C. Samples equivalent 
to 100/~g of heparin expressed as uronic acids were visualized  by 
staining with alcian blue. Reference standards were hyaluronic acid 
(which stays  at the origin), and heparan sulfate (HS) and chondroitin- 
6-sulfate (CS), both indicated in the figure. The gel was cleared and 
scanned at 605  nm  on a Canalco  integrating  scanner. (A) GAGs 
from the ECM fraction. (B) Sample after treatment with nitrous acid. 
(C) Sample digested with chondroitinase ABC. (D) Sample digested 
with chondroitinase ABC plus nitrous acid treatment. Two peaks 
were found; one of them co-migrates with heparan sulfate and the 
other with chondroitin-6-sulfate. Nitrous  acid treatment removed 
~40-50% of the HS peak, whereas chondroitinase ABC digestion 
removed 100% of the CS peak and ~50% of the HS peak. 
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to Nitrous Acid Treatment 
ECM-GAGs 
Treatment  HS peak  CS peak  HS 
°6  lOO ~g 
Control  50.1 + 4.8  49.9 _+ 4.8  100 
Nitrous acid  29.3 _+ 1.5  51.2 + 4.9  3 
The ECM-GAGs sample is equivalent  to  100 ~g of heparin expressed as 
uronic acids. The value for heparan sulfate (HS) and chondroitin  sulfate (CS) 
peaks in the control is the mean _+ S.D. of five different samples. The values 
for nitrous acid oxidation is the mean -  S.D. of four different samples. The 
nitrous acid treatment consisted of incubation of equal volumes of 1.0 M 
nitrous acid (made fresh as described in Material and Methods) with  ECM 
GAGs, for 3 h at room temperature. Either the control or the nitrous acid 
treated samples  were lyophilized to dryness. The samples were separated in 
cellulose acetate electrophoresis in 0.2 M calcium acetate buffer pH 7.0 at 
4°C.  For quantitative determination  of the GAGs, the strips were cleared, 
dried, and scanned on a Canalco densitometer. 
raphy on Sepharose CL-6B, and (d) the material sensitive to 
nitrous acid or heparitinase treatment is unaffected by chon- 
droitinase ABC. We have also demonstrated the existence of 
chondroitin  sulfate-type proteoglycans: in  fact, of the total 
sulfated GAGs present in the electric organ ECM,  80%  by 
electrophoretic analyses and  75%  by chromatography were 
sensitive to  chondroitinase  ABC  and  insensitive to  nitrous 
acid or heparitinase treatments. Moreover, by its migration 
in the calcium acetate system, the CS peak seems to be entirely 
of the 6-sulfate type (50%). The nitrous acid-resistant GAGs 
of the HS peak, because of its sensitivity to chondroitinase 
ABC,  probably correspond to dermatan  sulfate (30%),  but 
further studies are necessary to establish this point. 
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FIGURE  6  Sepharose-CL-6B  elution  profile  of  alkaline  borohy- 
dride-treated  FCM  from  electric  organ.  ECM-like  material  was 
hydrolyzed in  the  presence of 0.01  M  NaOH  and  1.0  M  NaBH4 
during 24 h at 45°C. Thereafter, the solution was neutralized, and 
the free GAGs were precipitated with cold 70% ethanol. Aliquots 
of  the  GAGs  were  either  directly  eluted  in  a  Sepharose  CL-6B 
column (A), eluted after heparitinase treatment (B), or after chon- 
droitinase  ABC  digestion  (C). Treatments  with  heparitinase  and 
chondroitinase ABC released ~18% and ~75% of the total uronic 
acid to the total column volume. Heparitinase treatment produces 
a decrease in the peak of K,v =  0.53, whereas chondroitinase ABC 
digestion produces a clear decrease in the peak of K,v =  0.3. 
DISCUSSION 
Our findings indicate that the  collagen-tailed AChE  of the 
electric organ of Discopyge is associated with the ECM  via 
heparan sulfate proteoglycans. Evidence has been presented 
showing  that  sulfated  GAGs  promoted  the  release  of the 
asymmetric AChE from purified basal lamina fractions. This 
result could be obtained if heparan sulfate or heparin com- 
peted with components of the ECM for binding sites on the 
collagenous tail of  the asymmetric ACHE. This model requires 
the formation of a GAG-enzyme complex and therefore, the 
existence of  a direct binding of  the GAG to ACHE. Our results 
are  consistent  with  the  above possibility; in  fact,  we  have 
obtained clear evidence for the existence of a  30S aggregate 
and  for specific binding  of the  collagen-tailed  AChE  to  a 
heparin-agarose resin. 
Since the sulfated GAG heparin is absent in tissues free of 
mast cells  (36)  and is normally an  intracellular compound 
(10),  the closely related component, heparan sulfate, may be 
the  molecule involved in  the  attachment  of AChE  to  the 
ECM.  Since  sulfated  GAGs  are  normally associated  to  a 
protein core (37), it is very likely that the cell surface heparan 
sulfate proteoglycans are the factors responsible for the an- 
chorage of ACHE.  In this context, our results showing that 
heparitinase,  an  enzyme that  degrades specifically heparan 
sulfate, releases asymmetric AChE from the ECM and that 
heparan sulfate is one of the carbohydrate components of the 
electric organ ECM proteoglycans, are ent!rely consistent with 
our earlier suggestion that heparan sulfate proteoglycans are 
involved in the attachment of the collagen-tailed AChE to the 
ECM of the neuromuscular junction (16). 
Previous studies with muscle cells and electric organ have 
shown that the asymmetric 16S AChE is associated with the 
ECM through its collagen-like tail (5, 6, 38). It has also been 
suggested that  the  aggregation of the  asymmetric AChE  at 
low ionic strength could be related to the immobilization of 
the molecules at the basal lamina (2). In the electric organ of 
Electrophorus,  the aggregation depends on a factor related to 
a GAG of the chondroitin sulfate type, which formed an 85S 
complex with AChE (13).  However, in mouse myotube cul- 
tures (5)  as well as in the ECM of Discopyge electric organ 
(this work), no substantial release of AChE was obtained after 
treatment with  chondroitinase  ABC.  We  have shown  here 
that sulfated GAGs release asymmetric AChE not as individ- 
ual 16S molecules, but as multimolecular aggregates (30S) of 
such molecules. In this context, Bon et al.  (13) have shown 
that  the  sedimentation  properties  of the  AChE  aggregates 
depend on the particular aggregating agent used. In fact, when 
Electrophorus  AChE interacts with heparin, it forms a com- 
plex of 100S, clearly different from the one observed in our 
experiments. However, when the so-called Electrophorus  ag- 
gregating  agent  of Bon  et  al.  (13)  was  added  to  purified 
Torpedo enzyme, the esterase forms aggregates with a  sedi- 
mentation coefficient of 30S, suggesting that the size of AChE 
aggregates depends not only on the aggregating agent, but also 
on the nature of the enzyme used. 
Regarding the mechanism of how the asymmetric AChE 
form, a molecule assembled intracellularly (33, 34, 39, 40) in 
the Golgi apparatus (34),  is incorporated into  an insoluble 
ECM,  one possibility could be the conversion of a  soluble 
secreted macromolecule to a complex array of AChE mole- 
cules (i.e.,  the AChE aggregates).  Such  a  conversion would 
probably require another ECM component that would cata- 
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role could be a heparan sulfate proteoglycan present on the 
cell surface. In this context, it has been shown that a conver- 
sion of soluble fibronectin to fibrillar  aggregates is catalyzed 
by heparin, which also enhances the binding of soluble fibro- 
nectin to the cell surface (4 l). 
Heparan  sulfate  proteoglycans  are  components  of basal 
lamina or ECM, for example, of the glomerulus (27), mam- 
mary epithelium  (42),  and  that  of a  basement  membrane 
producing tumor (43). In all of the above tissues, the heparan 
sulfates are the  main  component of the  ECM,  comprising 
~70%  of the total proteoglycans present. This does not seem 
to be the case for the electric organ ECM, in which only 20% 
of the total sulfated carbohydrate components of proteogly- 
cans correspond to heparan sulfate. Our studies on the chem- 
ical composition of the electric organ ECM showed the pres- 
ence  of an  important  amount  (80%)  of a  chondroitinase 
ABC-sensitive  material, which could be either chondroitin- 
4-sulfate, chondroitin-6-sulfate, or dermatan sulfate. Most of 
this sensitive ECM material migrated as chondroitin-6-sulfate 
(70%);  in this context, preliminary evidence from collabora- 
tive  studies  with  Dr.  C.  P.  Dietrich  and  co-workers also 
indicates the presence of chondroitin-6-sulfate proteoglycans 
in the ECM of the electric organ. So far, only a small amount 
of uncharacterized  chondroitin  sulfate  proteoglycans  have 
been observed in the glomerular basement membranes (26, 
27),  It seems, therefore, that the ECM of the electric organ 
has a  unique biochemical composition in terms of the car- 
bohydrate complement of its proteoglycans. 
Several interactions of matrix components could play a role 
in  the  deposition  of an  insoluble  ECM  (44-46),  and  the 
association of the  isolated tailed  AChE  with various ECM 
components has been studied. Binding occurs with chondroi- 
tin  sulfate (13),  fibronectin  (12,  14),  laminin (14),  collagen 
type V  (14), and heparan sulfate proteoglycan (14).  It must 
be taken into account, however, that Grassi et al.  (15) have 
been unable to find any binding at all of the collagen-tailed 
AChE with fibronectin,  laminin, and collagen type V.  The 
binding to heparan sulfate proteoglycan was not,  however, 
studied.  We consider that: (a)  heparan sulfate and heparin 
solubilize asymmetric AChE  from the ECM  of the electric 
organ  (present  work);  (b)  the  asymmetric  AChE  binds  to 
heparin-agarose ([35]; this work) and to heparan sulfate pro- 
teoglycans covalently bound to agarose (14); (c) heparitinase 
releases the collagen-tailed AChE from the electric organ ECM 
(present  work);  (d)  the  existence  of heparan  sulfate  as  a 
carbohydrate component of the electric organ ECM proteo- 
glycans (this work); and (e) a specific, saturable and reversible 
binding of asymmetric AChE to a single class of binding sites 
on cell surfaces rich in  heparan sulfate proteoglycans ([47]; 
Inestrosa,  N.  C.,  and  Z.  W.  Hall,  unpublished  results),  it 
appears very likely that the anchorage of collagen-tailed AChE 
to the synaptic ECM is mediated by heparan sulfate proteo- 
glycans. 
We thank Drs. I. Yamashina (Kyoto University, Sakyo-ku, Japan) 
and Robert D. Rosenberg (Massachusettes Institute of Technology, 
Cambridge, MA) for a sample of heparitinase. 
This investigation was supported by the Direccirn  de Investiga- 
clones de la Universidad Cat61ica de Chile (Grant No. 80/84),  the 
Fondo Nacional de Ciencias de Chile (Grant No. 1015/85), and by a 
grant from the Fundacirn Gildemeister to Dr. Inestrosa. Additional 
funding was provided by a Graduate Student Research Grant from 
the Direccirn de Investigaciones de la Universidad Cat61ica de Chile 
and a grant from United Nations Development Programme-United 
Nations Educational, Scientific, and Cultural Organization, both to 
E. Brandan. 
Received for publication 14 December 1984, and in revised form 14 
February 1985. 
REFERENCES 
1.  Kuffler, S. W., and J. O. Nicholls.  1979. From Neuron to Brain.  Sinuaer Associates, 
Inc., Sunderland,  MA. 
2.  Massoulir,  J, and S. Bon. 1982. The molecular forms ofcholinesteras¢ and acetyleholin- 
esterase in vertebrates.  Annu. Rev. Neurosci.  5:57-106. 
3.  Bon, S., M. Vigny, and J. Massoulir.  1979. Asymmetric and globular forms of acetyl- 
cholinesterase  in mammals  and birds. Proc. Natl. Acad Sci.  USA.  76:2546-2550. 
4.  Mays, C., and T. L  Rosenberry.  1981. Characterization of pepsin-resistant  collagen-like 
tail subunit fragments of 18S and 14S acetylcholinesterase  from Electrophorus  electricus. 
Biochemistry.  20:2810-2817. 
5.  Inestrosa,  N. C., L. Silberstein, and Z. W. Hall.  1982. Association  of the synaptie  form 
of acetylcholinesterase  with extracellular  matrix in cultured mouse muscle cells. Cell. 
29:71-79. 
6.  Inestrosa,  N. C., and B. Mrndez. 1983. The AI2 acetylcholinesterase  and polypeptide 
composition of electric  organ basal lamina of Electrophorus  and some Torpedinidae 
fishes. Cell Biochem.  Funct.  1:41--48. 
7.  Hay, E. D. 1981. Extracellular  matrix. J. Cell Biol.  91:205s-223s. 
8.  Hynes, R. O., and K. M. Yamada. 1982. Fibronectins:  multifunctional  modular glyco- 
proteins. J. Cell Biol.  95:369-377. 
9,  Kleinman, H. K., R. J. Klebe, and G. R. Martin. 1981. Role of collagenous  matrices in 
the adhesion and growth of cells. J. Cell Biol.  88:473-485. 
10.  Yamada, K. M.  1983. Cell surface interactions  with extracenular materials. Annu. Rev. 
Biochem.  52:761-799. 
I 1.  Timpl, R., M. Dziadek,  S. Fujiwara,  H. Nowack, and S. Wick.  1983. Nidogen:  a new, 
self-aggregating basement membrane protein.  Eur. J. Biochem.  137:455-465. 
12.  Emmerling, M. R., C. D. Johnson, D. F. Mosher,  B. H. Lipton, and J. E. Lilien.  1981. 
Cross-linking and binding offibronectin with asymmetric  acetyleholinesterase.  Biochem- 
istry. 20:3242-3247. 
13.  Bon,  S., J. Cartaud, and J. Massouli~.  1978. The dependence of acetylcholinesterase 
aggregation at low ionic strength upon a polyanionic component. Eur. J. Biochem.  20:1- 
14. 
14.  Vigny, M,,  G. R. Martin, and G. R. Grotendorst.  1983. Interactions of asymmetric 
forms of acetylcholinesterase  with basement membrane components. J.  Biol.  Chem. 
258:8794-8798. 
15. Grassi, J., J. Massoulir,  and R. Timpl. 1983. Relationship  of collagen-tailed  acetylcho- 
linesterase with basal lamina components. Absence of binding with laminin, fibronectin 
and collagen types IV and V and lack of reactivity with different anti-collagen  sera. Eur. 
J. Biochem  133:31-38. 
16.  Tones, J. C., and N. C. Inestrosa.  1983. Heparin solubilizes  asymmetric acetyleholin- 
esteras¢  from rat  neuromuscular junction.  FEBS  (Fed.  Eur.  Biochem.  Soc.)  Lett. 
154:265-268. 
17.  Mrndez, B., J. Garrido, M.  Maldonado, F. Jaksic,  and N. C. Inestrosa.  1984. The 
electric organ of Discopyge  tschudii:  its innervated face and the biology of acetylcholin- 
esterase. Cell. Mol. Neurobiol.  4:125-142. 
18.  lnestrosa,  N. C.,  B. M~ndez,  and J. V. Loeo.  1979. Acetylcholinesterase  like that of 
skeletal  muscle in  smooth muscle reinnervated by a  motor nerve. Nature  (Loud.). 
28@504-506. 
19.  lnestrosa,  N.  C.,  C.  G.  Reiness,  L.  F.  Reichardt,  and  Z.  W.  Hall.  1981. Cellular 
localization  of the molecular forms of ace~ylcholinesterase  in rat pheochromocytoma 
PCI2 cells treated with nerve growth factor. J. NeuroscL  I:1260-1267. 
20.  Craven, G. R., E. Steers Jr., and C. B. Anfinsen.  1965. Purification  composition and 
molecular  weight  of the  tJ-galactosidase  of Escherichia  coli  KI2.  J.  BioL  Chem. 
240:2468-2477. 
21.  Ellman, G. L., K. D. Courtney, V. Andres, and R. M. Featherstone.  1961. A new and 
rapid colorimetric determination of acetylcholinesterase  activity.  Biochem.  PharmacoL 
7:88-95. 
22.  Carlson,  D. M.  1968. Structures  and immunochemical properties  of oligosaecharides 
isolated from pig submaxillary  mucins. J. Biol.  Chem. 243:616-626. 
23.  Saito,  H., T. Yamata, and S. Suzuki.  1968. Enzymatic methods for the determination 
of small quantities  of isomeric chondroitin sulfates. J. Biol.  Chem. 243:1536-1542. 
24.  Rapraeger, A., E. Endo, J. Koch, and M. Bernfield.  1985. The cell surface proteoglycan 
from mouse mammary epithelial  cells  bears chondroitin sulfate  and heparan sulfate 
glycosaminoglycans.  J. Biol.  Chem. In press. 
25.  Cifonelli,  J.  A.,  and J.  King  1972.  Distribution  of 2-acetoamido-2-deoxy-O-glucose 
residues in mammalian heparins.  Carbohydr.  Res 21 : 173-186. 
26.  Kanwar, Y. S., V. C. Hascall,  and M. G. Farquhar.  1981. Partial  characterization  of 
newly synthesized  proteoglycans  isolated  from the glomerular basement membrane..L 
Cell Biol.  9@527-532. 
27.  Kanwar, Y. S., and M. G. Farquhar. 1979. Isolation  of glycosaminoglycans  (heparan 
sulfate) from glomerular basement membranes. Proc. Natl.  Acad  Sci.  USA.  76:4493- 
4497. 
28.  Yanagishita,  M., and V.  C.  Hascall.  1983. Characterization  of low buoyant density 
dermatan sulfate proteoglycans  synthesized  by rat ovarian granulosa cells in culture.  J. 
Biol.  Chem. 258:12847-12856. 
29.  Bitter,  T., and H. M.  Muir.  1962. A  modified  uronic acid carbazole  reaction.  Anal. 
Biochem.  4:330-334. 
30.  Ehrlich, J,, and S. S. Stivala.  1973. Chemistry and pharmacology of heparin. ,L Pharm. 
Sci.  62:517-544. 
31.  Younkin, S. G., C.  Rosenstein,  P.  L. Collins,  and T. L. Rosenberry.  1982. Cellular 
localization  of the molecular forms of acetylcholinesterase  in rat diaphragm. J.  Biol. 
Chem. 257:13630-13637. 
32.  Fernhndez,  H. L, N. C. Inestrosa,  and J. R. Stiles.  1984. Subcellular  localization  of 
acetylcholinesterase  molecular forms in endplate regions of adult mammalian skeletal 
muscle. Neurochem.  Res. 9:1211-1230. 
33.  Inestrosa,  N. C. 1984. 16S Acetylcholinesterase  of the extracellular  matrix is assembled 
within mouse muscle ceils. Biochem.  J. 217:377-381. 
BRANDAN  ET  AL.  AChE-Heparan Interaction in the Extracellular Matrix  991 34.  Rotundo,  R.  L.  1984. Asymmetric acetylcholinesterase  is  assembled in  the  Golgi 
apparatus. Proc. NatL Acad. Sci.  USA. 81:479--483. 
35.  Brandan, E., and N. C. lnestrosa.  1984. Binding of the asymmetric forms of acetylcho- 
linesterase  to heparin. Biochem. J. 221:415--422. 
36.  Straus, A. H., H. B. Nader, and C. P. Dietrich.  1982. Absence ofheparin-like compounds 
in mast-cell-free tissue and animals. Biochim.  Biophys. Acta. 717:478--485. 
37.  H66k, M., L. Kjellrn, S. Johansson,  and J. Robinson. 1984. Cell-surface glycosamino- 
glycans, Annu. Rev. Biochem.  53:847-869. 
38.  Lwebuga-Mukasa,  J. S., S. Lappi, and P. Taylor. 1976. Molecular forms of acetylcholin- 
esterase from Torpedo californiea: their relationship  to synaptie membranes. Biochem- 
istry.  15:1425-1434. 
39.  Fernhndez,  H. L.,  and J.  R. Stiles.  1984.  lntra-versus extmcellular recovery of 16S 
acetylcholinesterase  following organophosphate inactivation in the rat. Neurosci.  Lett. 
49:117-122. 
40.  Inestrosa,  N. C., W. D. Matthew, C. G. Reiness, Z. W. Hall, and L. F. Reichardt. 1985. 
Atypical distribution  of asymmetric acetylcholinesterase  in mutant PC 12 pheoehromo- 
cytoma cells lacking a cell surface heparan sulfate  proteoglycan.  ,L Neurochem.  45. In 
press. 
41.  Jilek, F, and H. Hbrmann. 1979. Fibronectin (cold insoluble globulin).  VI, Influence of 
hepann and hyaluronie acid on the binding to native collagen. Hoppe-Seyler's  Z. Physiol. 
Chem, 360:597-603, 
42. Gordon. J. R., and M. Bernfield.  1980. The basal lamina of the post-natal  mammary 
epithelium contains glyeosaminoglyeans  in a precise ultrastructural  organization.  Dee. 
Biol. 74:118-135. 
43.  Hassell, J. R., P. G, Robey, H, J. Barrach, J. Wilezek, S. 1. Rennard, and G. R. Martin. 
1980. Isolation  ofa heparan sulfate containing proteoglycan  from basement membrane. 
Proc. Natl. Acad. Sci.  USA. 77:4494-4498. 
44.  Perkins,  M. E., T. H. Ji, and R. O. Hynes. 1979. Crossqinking  of fibronectin  to sulfated 
proteoglycans  at cell surface. Cell. 16:941-952. 
45.  Ruoslahti,  E., and E. Engvall. 1980. Complexing of fibronectin,  glycosaminoglycans  and 
collagen. Biochim.  Biophys, Acta. 631:350-358. 
46.  Kleinmam, H. K., M. L. McGarvey, J. R. Hassell, and G. R. Martin. 1983. Formation 
of a supramolecular complex is involved in the reconstitution  of basement membrane 
componentS.  Biochemistry.  22:4969--4974, 
47.  Brandan,  E.,  and N.  C.  Inestrosa.  1985. The synaptic form of acetylcholinesterase 
interacts with cell surface heparan sulfate proteoglycans.  J. Neurosci. Res. In press. 
99"~  THE JOURNAL OF CELL BIOLOGY .  VOLUME 101, 19B5 